Despite extensive literature on the impact of genetic variants in APOE, GBA, MAPT, and SNCA on cognitive progression in PD, large studies with prospective follow-up from the time of PD diagnosis are scarce and many studies track patients solely from a clinical environment. This evidence concerns the gene APOE and Parkinson disease.